MGMT and brain cancer: Cancer system characterizations have allowed the identification of some key components involved in brain cancer, such as the epidermal growth factor receptor, <i>BRAF</i>, platelet-derived growth factor receptor alpha, <i>TP53</i>, O6-methylguanine-DNA methyltransferase, cyclin-dependent kinase 1/2/3/4, cyclooxygenase 1/2, vascular endothelial growth factor receptor 2, telomerase reverse transcriptase, and CYP2D6, along with the U87 cell line.